Advisor Group’s Iovance Biotherapeutics IOVA Stock Holding History

Advisor Group’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$129K	Buy	4,661 +100	+2%	+$2.27K	﹤0.01%	2744
2019 Q3	$83K	Hold	4,561	–	–	﹤0.01%	3028
2019 Q2	$111K	Sell	4,561 -3,557	-44%	-$53.6K	﹤0.01%	2780
2019 Q1	$78K	Hold	8,118	–	–	﹤0.01%	3064
2018 Q4	$72K	Buy	8,118 +3,000	+59%	+$28.9K	﹤0.01%	2916
2018 Q3	$58K	Sell	5,118 -3,578	-41%	-$50.8K	﹤0.01%	3169
2018 Q2	$111K	Sell	8,696 -5,473	-39%	-$80K	﹤0.01%	2450
2018 Q1	$239K	Buy	14,169 +11,619	+456%	+$176K	﹤0.01%	1842
2017 Q4	$20K	Sell	2,550 -450	-15%	-$3.61K	﹤0.01%	3717
2017 Q3	$23K	Buy	+3,000	New	+$19K	﹤0.01%	3481

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advisor Group's IOVA Position: Q4 2019 in Review

Advisor Group increased its Iovance Biotherapeutics (IOVA) stake by 2.2% in Q4 2019, buying an estimated $2.27K and bringing the position to 4,661 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #2744.

Advisor Group first reported a position in IOVA in Q3 2017 and has held it in 10 quarters since. The position peaked at $239K in Q1 2018. 200 funds tracked by Wall St. Rank hold IOVA as of Q4 2019.

Advisor Group held 4,661 shares of Iovance Biotherapeutics worth $129K as of Q4 2019.
Advisor Group bought 100 Iovance Biotherapeutics shares in Q4 2019, an estimated $2.27K.
Iovance Biotherapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #2744 holding.
Advisor Group first reported a position in Iovance Biotherapeutics in Q3 2017 and has held it in 10 quarters since.
Advisor Group's Iovance Biotherapeutics position peaked at $239K in Q1 2018.
200 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.